A study to investigate the safety and efficacy of study drug OMS721 in adults and adolescents with Atypical Hemolytic Uremic Syndrome. A study to investigate the safety and efficacy of study drug OMS721 in adults and adolescents with A ...
A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents. A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolyti ...
Product Code: OMS721 Drug Product 185 mg/mL INN or Proposed INN: not yet available Other descriptive name: OMS00620646, OMS620646, MASP-2 Antibody Product Code: OMS721 Drug Product 185 mg/mL INN or Proposed INN: not yet available Other descriptive name: OMS00620646, OMS620646, MASP-2 Antibody Product Code: OMS721 Drug Product 185 mg/mL INN or Proposed INN: not yet available Other descriptive n ...
A study to investigate the safety and efficacy of study drug OMS721 in adults and adolescents with Atypical Hemolytic Uremic Syndrome. A study to investigate the safety and efficacy of study drug OMS721 in adults and adolescents with A ...
A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents. A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolyti ...
Product Code: OMS721 Drug Product 185 mg/mL INN or Proposed INN: not yet available Other descriptive name: OMS00620646, OMS620646, MASP-2 Antibody Product Code: OMS721 Drug Product 185 mg/mL INN or Proposed INN: not yet available Other descriptive name: OMS00620646, OMS620646, MASP-2 Antibody Product Code: OMS721 Drug Product 185 mg/mL INN or Proposed INN: not yet available Other descriptive n ...
Omeros Corporation
NULL
Authorised-recruitment may be ongoing or finished
Female: yes Male: yes
80
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...